Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vupanorsen PK/PD in Healthy Chinese Adults
NCT04916795Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vupanorsen in hypertriglyceridemia (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time 0 to 24 Hours Post-dose, Area Under the Curve From Time 0 to 48 Hours Post-dose and 7 more. Started Jun 2021; status: completed.
02
Drugs
vupanorsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT04916795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04916795.